Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study

Hong, Kyung Soo; Lee, Kwan Ho; Chung, Jin Hong; Shin, Kyeong-Cheol; Choi, Eun Young; Jin, Hyun Jung; Jang, Jong Geol; Lee, Wonhwa; Ahn, Jae‐Jun

doi:10.3349/ymj.2020.61.5.431

Cited by 139 publications

(178 citation statements)

References 15 publications

Supporting

Mentioning

153

Contrasting

Unclassified

Order By: Relevance

“…The incidence of AKI in ICU patients with the COVID-19 was particularly high range from 8%-62% 15,18,[23][24][25]28,29 . Critical ill patients hospitalized with COVID-19, requiring ventilator is more likely to develop AKI 4 .…”

Section: Discussionmentioning

confidence: 99%

“…Overall, COVID-19 patients were included in our meta-analysis. [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] The pooled estimated incidence of AKI in all hospitalized COVID-19 patients was 12.0% (95% CI: 9.0%-15.0%, Fig. 2), and a signi cant heterogeneity (I 2 = 98%, Chi-square = 0.19, P < 0.01) was observed ( Table 3).…”

Section: Literature Search and Study Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Whether Remdesivir Increases the Risk of Acute Kidney Injury (AKI) in Patients with COVID-19: A Systematic Review and Meta-Analysis

Xu¹,

Tang²,

Huang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Acute kidney injury (AKI) occurs among patients with COVID-19, it is also proved to be associated with in-hospital mortality. Remdesivir, an RNA polymerase inhibitor, has shown its antiviral activity in vitro and animal models. The adverse effect of Remdesivir especially AKI is the most common cause which lead to drug discontinuation. Whether Remdesivir increases the risk of AKI in patients with COVID-19 is not clear. We conducted a systematic review and meta-analysis to evaluate the incidence rate of AKI in hospitalized COVID-19 patients and whether Remdesivir increases the risk of AKI. Methods: A thorough search was carried out to find relevant studies in PubMed, medRxiv, and Web of Science from 1 Jan 2020 till 1 June 2020. 15135 COVID-19 patients and 981 COVID-19 patients using Remdesivir were included in our meta-analysis. Results: The pooled estimated incidence of AKI in all hospitalized COVID-19 patients was 12.0% (95% CI:9.0%-15.0%). According to our subgroup study, the incidence of AKI was associated with the age, disease severity and race of patients. The incidence of AKI in hospitalized COVID-19 patients using Remdesivir was 6% (95% CI: 3%-13%) with a total of 5 studies. Comparing with COVID-19 patients without Remdesivir treatment, Remdesivir treatment do not increase the risk of AKI in COVID-19 patients showing OR 0.80(95%CI: 0.44-1.46, P>0.05). Conclusions: We found out that AKI was not rare in hospitalized COVID-19 patients. The incidence of AKI was associated with age, disease severity and race. Remdesivir treatment did not increase the risk of AKI in hospitalized COVID-19 patients. Our meta-analysis may provide an evidence for future study that AKI is associated with the natural cause of COVID-19, not the adverse event after the usage of Remdesivir.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Literature Search and Study Characteristicsmentioning

confidence: 99%

Whether Remdesivir Increases the Risk of Acute Kidney Injury (AKI) in Patients with COVID-19: A Systematic Review and Meta-Analysis

Xu¹,

Tang²,

Huang³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Early case series from the Korean Cohort Study showed that 21.4% of patients received oxygen therapy, with no requirement for MV [14]. In the Daegu and Gyeongbuk area, Republic of Korea, substantial community outbreaks were linked to a large religious meeting, and a retrospective study from that area (mean age of 55.4±17.1 years) showed that 13.3% of patients required ICU admission with MV use in 11.2%, ECMO in 4.1%, and a mortality rate of 5.1% [15]. The fatality rate of South Korea, which is 2.32%…”

Section: Discussionmentioning

confidence: 99%

Predictive Parameters for the Worsening Clinical Course of Mild COVID-19 Pneumonia

Hahm¹,

Lee²,

Oh³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: This study aimed to determine parameters for worsening oxygenation in mild COVID-19 pneumonia.Methods: This retrospective cohort study included confirmed COVID-19 pneumonia in a single public hospital in South Korea from January to April 2020. Parameters were compared between the two groups on the basis of clinical course: the desaturation group was defined as those with oxygen saturation ≤ 94% on ambient air, or received oxygen or mechanical ventilation (MV) throughout the clinical course versus the nonevent group who were without any respiratory event up to 28 days. The severity and extent of viral pneumonia from an initial single chest CT were calculated using artificial intelligence (AI) algorithms and measured visually by a radiologist. Results: We included 136 patients with 32 (23.5%) in the desaturation group, of whom two needed MV and one died. Initial vital signs and duration of symptoms showed no difference between the two groups, however, univariate logistic regression analysis revealed that a variety of parameters at admission were associated with an increased risk of a desaturation event. In a sex-, age-, and comorbid illness-matched case-control study, ferritin ≥ 280 μg/L (OR 3.600, 95% CI 1.142-11.346; p=0.029), LDH≥ 240 U/L (OR 3.600, 95% CI 1.142-11.346; p=0.029), pneumonia burden (OR 1.010, 95% CI 1.002-1.019; p=0.021), and extent (OR 1.194, 95% CI 1.017-1.401; p=0.030) by AI, and visual severity scores (OR 1.146, 95% CI 1.005-1.307; p=0.042) were the predictive parameters for worsening clinical course with desaturation. Conclusion: Our study presents initial CT parameters measured by AI or visual severity scoring as well as serum markers of inflammation at admission as the best parameters for predicting worsening oxygenation in the COVID-19 pneumonia cohort. Initial chest CT scans may help clinicians diagnose viral pneumonia and evaluate the prognosis in mild COVID-19.

show abstract

“…Currently documented COVID-19 related complications include ARDS, arrhythmia, Septic shock, acute cardiac injury, myocarditis, acute coronary syndrome, cardiomyopathy, acute respiratory injury, and acute renal injury, etc [58,64,67,69,70,100]. The ARDS was the most common complication, among both mild and severe patients [58,64,67,69,70]. Most ICU patients had a higher risk of developing ARDS and having complications [12,70].…”

Section: Common Complicationsmentioning

confidence: 99%

Epidemiologic, Clinical, and Laboratory Findings of the COVID-19 in the current pandemic: Systematic Review and Meta-analysis

Xie

Wang

Liao

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The COVID-19 pandemic has affected the world deeply, with more than 3,000,000 people infected and nearly 200,000 deaths. This review aimed to summarize the epidemiologic traits, clinical spectrum, CT results and laboratory findings of the COVID-19 pandemic. Methods: We scoped for relevant literatures published during 1 st Dec 2019 to 23 rd Apr 2020 based on four databases using English and Chinese languages. We reviewed and analyzed the relevant clinic outcomes of COVID-19. Results: The COVID-19 pandemic was found to have a higher transmission rate compared to SARS and MERS and involved 4 stages of evolution. The basic reproduction number (R 0 ) is 3.32 (95% CI:3.24-3.39), the incubation period was 5.24 days (95% CI:3.97-6.50, 5 studies) on average, and the average time for symptoms onset varied by countries. Common clinical spectrums identified included fever (38.1-39.0℃), cough and fatigue, with Acute Respiratory Distress Syndrome (ARDS) being the most common complication reported. Body temperatures above 39.0 ℃, dyspnea, and anorexia were more common symptoms in severe patients. Aged over 60 years old, having co-morbidities, and developing complications were the commonest high-risk factors associated with severe conditions. Leucopenia and lymphopenia were the most common signs of infection while liver and kidney damage were rare but may cause bad outcomes for patients. The bilateral, multifocal Ground-Glass Opacification (GGO) on peripheral, and the consolidative pulmonary opacity were the most frequent CT results and the tendency of mortality rates differed by region. Conclusions: We provided a bird’s-eye view of the COVID-19 during the current pandemic, which will help better understanding the key traits of the disease. The findings could be used for disease’s future research, control and prevention.

show abstract

Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study

Cited by 139 publications

References 15 publications

Whether Remdesivir Increases the Risk of Acute Kidney Injury (AKI) in Patients with COVID-19: A Systematic Review and Meta-Analysis

Whether Remdesivir Increases the Risk of Acute Kidney Injury (AKI) in Patients with COVID-19: A Systematic Review and Meta-Analysis

Predictive Parameters for the Worsening Clinical Course of Mild COVID-19 Pneumonia

Epidemiologic, Clinical, and Laboratory Findings of the COVID-19 in the current pandemic: Systematic Review and Meta-analysis

Contact Info

Product

Resources

About